Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease

European Heart Journal

Volumn 27, Issue 7, 2006, Pages 817-823

  Koga, Hidenobu ^a   Sugiyama, Seigo ^a   Kugiyama, Kiyotaka ^b   Fukushima, Hironobu ^a   Watanabe, Keisuke ^a   Sakamoto, Tomohiro ^a   Yoshimura, Michihiro ^a   Jinnouchi, Hideaki ^c   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c Jinnouchi Hospital   (Japan)

Author keywords

Diabetes mellitus; Platelet derived microparticles; Remnant lipoprotein

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; GLYCOPROTEIN IB ALPHA; LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DYSLIPIDEMIA; FEMALE; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

ANGINA PECTORIS; ANTILIPEMIC AGENTS; BEZAFIBRATE; BLOOD PLATELETS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 33645024970     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi746     Document Type: Article

References (36)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
2. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696.
3. Battisti WP, Palmisano J, Keane WE. Dyslipidemia in patients with type 2 diabetes, relationships between lipids, kidney disease and cardiovascular disease. Clin Chem Lab Med 2003;41:1174-1181.
4. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-2016.
5. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-1146.
6. Havel RJ. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol 2000;11:615-620.
7. Fukushima H, Sugiyama S, Honda O, Koide S, Nakamura S, Sakamoto T, Yoshimura M, Ogawa H, Fujioka D, Kugiyama K. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. J Am Coll Cardiol 2004;43:2219-2224.
8. Hodis HN. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation 1999;99:2852-2854.
9. Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 2001;42:17-21.
10. Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, Tsunoda R, Sakamoto T, Nakano T, Nakajima K, Ogawa H, Sugiyama S, Yoshimura M, Yasue H. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999;99:2858-2860.
11. Doi H, Kugiyama K, Oka H, Sugiyama S, Ogata N, Koide SI, Nakamura SI, Yasue H. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 2000;102:670-676.
12. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diab Care 2001;24:1476-1485.
13. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003;108:1527-1532.
14. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-2581.
15. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
16. Englyst NA, Taube JM, Aitman TJ, Baglin TP, Byrne CD. A novel role for CD36 in VLDL-enhanced platelet activation. Diabetes 2003;52:1248-1255.
17. Saniabadi AR, Umemura K, Shimoyama M, Adachi M, Nakano M, Nakashima M. Aggregation of human blood platelets by remnant like lipoprotein particles of plasma chylomicrons and very low density lipoproteins. Thromb Haemost 1997;77:996-1001.
18. Knofler R, Nakano T, Nakajima K, Takada Y, Takada A. Remnant-like lipoproteins stimulate whole blood platelet aggregation in vitro. Thromb Res 1995;78:161-171.
19. Yamazaki M, Uchiyama S, Xiong Y, Nakano T, Nakamura T, Iwata M. Effect of remnant-like particle on shear-induced platelet activation and its inhibition by antiplatelet agents. Thromb Res 2005;115:211-218.
20. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res 2003;59:277-287.
21. Preston RA, Jy W, Jimenez JJ, Mauro LM, Horstman LL, Valle M, Aime G, Ahn YS. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 2003;41:211-217.
22. Nomura S, Suzuki M, Katsura K, Xie GL, Miyazaki Y, Miyake T, Kido H, Kagawa H, Fukuhara S. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 1995;116:235-240.
23. Minagar A, Jy W, Jimenez JJ, Sheremata WA, Mauro LM, Mao WW, Horstman LL, Ahn YS. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 2001;56:1319-1324.
24. Tramontano AF, O'Leary J, Black AD, Muniyappa R, Cutaia MV, El-Sherif N. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. Biochem Biophys Res Commun 2004;320:34-38.
25. Fox JE, Aggerbeck LP, Berndt MC. Structure of the glycoprotein Ib.IX complex from platelet membranes. J Biol Chem 1988;263:4882-4890.
26. Nomura S, Uehata S, Saito S, Osumi K, Ozeki Y, Kimura Y. Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost 2003;89:506-512.
27. Diamant M, Tushuizen ME, Sturk A, Nieuwland R. Cellular microparticles: new players in the field of vascular disease? Eur J Clin Invest 2004;34:392-401.
28. Doi H, Kugiyama K, Ohgushi M, Sugiyama S, Matsumura T, Ohta Y, Nakano T, Nakajima K, Yasue H. Remnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation. Atherosclerosis 1998;137:341-349.
29. De La Cruz JP, Arrebola MM, Villalobos MA, Pinacho A, Guerrero A, Gonzalez-Correa JA, Sanchez de la Cuesta F. Influence of glucose concentration on the effects of aspirin, ticlopidine and clopidogrel on platelet function and platelet-subendothelium interaction. Eur J Pharmacol 2004;484:19-27.
30. Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 1998;91:484-490.
31. Ruef J, Peter K, Nordt TK, Runge MS, Kubler W, Bode C. Oxidative stress and atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic approaches. Thromb Haemost. 1999;82(Suppl. 1):32-37.
32. Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004;2:1282-1291.
33. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002;288:2008-2014.
34. Strowig SM, Aviles-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diab Care 2002;25:1691-1698.
35. Annuzzi G, De Natale C, lovine C, Patti L, Di Marino L, Coppola S, Del Prato S, Riccardi G, Rivellese AA. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2004;24:2397-2402.
36. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165:1154-1160.